Eosinophilia Myalgia Syndrome (EMS) caused by L-Tryptophan product and Toxic Oil Syndrome (TOS) caused by denatured rape-seed oil 20 years after outbreak of EMS

Journal of the Food Hygienic Society of Japan

Volumn 50, Issue 6, 2009, Pages 279-291

  Maitani, Tamio ^a   Saitoh, Hiroshi ^b  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b SAGAMIHARA NATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLAMINO 1,2 PROPANEDIOL; 3-PHENYLAMINO-1,2-PROPANEDIOL; ANILINE; ANILINE DERIVATIVE; PROPANEDIOL DERIVATIVE; RAPESEED OIL; TRYPTOPHAN; VEGETABLE OIL;

ANIMAL; EOSINOPHILIA MYALGIA SYNDROME; EPIDEMIC; FEMALE; FOOD CONTAMINATION; HUMAN; MALE; REVIEW; SYNDROME; TIME;

ANILINE COMPOUNDS; ANIMALS; DISEASE OUTBREAKS; EOSINOPHILIA-MYALGIA SYNDROME; FEMALE; FOOD CONTAMINATION; HUMANS; MALE; PLANT OILS; PROPYLENE GLYCOLS; SYNDROME; TIME FACTORS; TRYPTOPHAN;

BRASSICA NAPUS;

EID: 75749127824     PISSN: 00156426     EISSN: None     Source Type: Journal    
DOI: 10.3358/shokueishi.50.279     Document Type: Review

References (61)

1. Uchiyama, M. Progress report of the studies in Japan on eosinophilia-myalgia syndrome caused by L-tryptophan product. Shokuhin Eiseigaku Zasshi (J. Food Hyg. Soc. Japan), 40, 335-355 (1999).
2. Centers for Disease Control and Prevention. Epidemiologic Notes and Reports Eosinophilia-Myalgia Syndrome-New Mexico, MMWR (November 17), 38, 765-767 (1989).
3. Centers for Disease Control and Prevention. Epidemiologic Notes and Reports Eosinophilia-Myalgia Syndrome and L-Tryptophan-Containing Products-New Mexico, Minnesota, Oregon, and New York, MMWR (November 24), 38, 785-788 (1989).
4. Mizutani, T., Mizutani, H., Hashimoto, K., Nakamura, Y., Kishida, M., Taniguchi, H., Murata, M., Kuzuhara, S., Shimizu, M. Simultaneous development of two cases of eosinophilia-myalgia syndrome with the same lot of L-tryptophan in Japan. J. Am. Acad. Dermatol., 25, 512-517 (1991).
5. Mizutani, T., Mizutani, H., Hashimoto, K., Kishida, M., Taniguchi, H., Okada, H., Murata, M., Nakamura, Y., Shimizu, M. Two cases of L-tryptophan ingestion induced induced eosinophilia-myalgia syndrome. Nippon Hifuka Gakkai Zasshi, 101, 561-566 (1991).
6. Ishikawa, A., Akahosi, T., Okada, J., Kondo, H., Kasiwazaki, S. A case of the eosinophilia-myalgia syndrome. Ryumachi. 32, 327-330 (1992).
7. Slutsker, L., Hoesly, F. C., Miller, L., Williams, L. P., Watson, J. C., Fleming, D. W. Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer. JAMA, 264, 213-217 (1990). (Pubitemid 20212581)
8. Toyo'oka, T., Yamazaki. T., Tanimoto, T., Sato, K., Sato, M., Toyoda, M., Ishibashi, M., Yoshihira, K., Uchiyama, M. Characterization of contaminants in EMSassociated L-tryptophan samples by high-performance liquid chromatography. Chem. Pharm. Bull., 39, 820-822 (1991).
9. Goda, Y., Suzuki, J., Maitani, T., Yoshihira, K., Takeda, M., Uchiyama, M. 3-Anilino-L-alanine, structural determination of UV-5, a contaminant in EMS-associated Ltryptophan samples. Chem. Pharm. Bull., 40, 2236-2238 (1992).
10. Belongia, E. A., Hedberg, C. W., Gleich, G. J., White. K. E., Mayeno, A. N., Loegering, D. A., Dunnette, S. L., Pirie, P. L., MacDonald, K. L., Osterholm, M. T. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N. Engl. J. Med., 323, 357-365 (1990).
11. Mayeno, A. N., Lin, F., Foote, C. S., Loegering, D. A., Ames, M. M., Hedberg, C. W., Gleich, G. J. Characterization of "peak E," a novel amino acid associated with eosinophilia-myalgia syndrome. Science, 250 (4988), 1707-1708 (1990).
12. Williamson, B. L., Johnson, K. L., Tomlinson, A. J., Gleich, G. J., Naylor, S. On-line HPLC-tandem mass spectrometry structural characterization of case-associated contaminants of L-tryptophan implicated with the onset of eosinophilia-myalgia syndrome. Toxicol. Lett., 99, 139-150 (1998).
13. Naylor, S., Johnson, K. L., Williamson, B. L., Klarskov, K., Gleich, G. J. Structural characterization of contaminants in commercial preparations of melatonin by online HPLC-electrospray ionization-tandem mass spectrometry. Adv. Exp. Med. Biol.. 467, 769-777 (1999).
14. Sullivan,E.A.,Staehling,N.,Philen,R.M.Eosinophiliamyalgiasyndromeamongthenon-L-tryptophanusersandpre-epidemiccases.J.Rheumatol.,23,1784-1787(1996).(Pubitemid26342453)
15. Saito, H., Tsurikisawa, N., Tsuburai, T., Akiyama, K. Involvement of regulatory T cells in the pathogenesis of Churg-Strauss syndrome. Int. Arch. Allergy Immunol., 146 (Suppl. 1), 73-76 (2008).
16. Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., Ouyang, W. Interleukin-22, a T(H) 17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature, 445 (7128), 648-651 (2007).
17. + T cells from patients with active Churg-Strauss syndrome tends toward Th 17. Int. Arch. Allergy Immunol., 149 (Suppl. 1), 61-65 (2009).
18. Chung, D. J., Rossi, M., Romano, E., Ghith, J., Yuan, J., Munn, D. H., Young, J. W. Indoleamine 2,3-dioxygenaseexpressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood, 114, 555-563 (2009).
19. Gross, B., Ronen, N., Honigman, S., Livne, E. Tryptophan toxicity-Time and dose response in rats. Adv. Exp. Med. Biol., 467. 507-516 (1999).
20. Smith, M. J., Garrett, R. H. A heretofore undisclosed crux of eosinophilia-myalgia syndrome: Compromised histamine degradation. Inflamm. Res., 54, 435-450 (2005).
21. Sattler, J., Lorenz, W. Intestinal diamine oxidases and enteral-induced histaminosis: Studies on three prognostic variables in an epidemiological model. J. Neural. Transm. Suppl., 32, 291-314 (1990).
22. Amor, B., Rajzbaum, G., Poiraudeau, S., Haas, C., Kahan, A. Eosinophilia-myalgia linked with Ltryptophan. Lancet, 335 (8686), 420-421 (1990).
23. Sternberg, E. M., Van Woert, M. H., Young, S. N., Magnussen, I., Baker, H., Gauthier, S., Osterland, C. K. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N. Engl. J. Med., 303, 782-787 (1980).
24. Michelson, D., Page, S. W., Casey, R., Trucksess, M. W., Love, L. A., Milstien, S., Wilson, C., Massaquoi, S. G. Crofford, L. J., Hallett, M., Gold, P. W., Sternberg, S. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. J. Rheumatol., 21, 2261-2265 (1994).
25. Williamson, B. L., Klarskov, K., Tomlinson, A. J., Gleich, G. J., Naylor, S. Problems with over-the-counter 5-hydroxy-tryptophan. Nature Med., 4, 983 (1998).
26. Johnson, K. L., Klarshov, K., Benson, L. M., Williamson, B. L., Gleich, G. J., Naylor, S. Presence of peak X and related compounds: The reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. J. Rheumatol., 26, 2714-2716 (1999).
27. Klarskov. K., Johnson, K. L., Benson, L. M., Cragun, J. D., Gleich, G. J., Wrona, M., Jiang, X. R., Dryhurst, G., Naylor, S. Structural characterization of a case-implicated contaminant, "Peak X," in commercial preparations of 5-hydroxytryptophan. J. Rheumatol, 30, 89-95 (2003).
28. Das, Y. T., Bagchi, M., Bagchi, D., Preuss, H. G. Safety of 5-hydroxy-L-try-ptophan. Toxicol. Lett., 150, 111-122 (2004).
29. Naylor, S., Johnson, K. L., Williamson, B. L., Klarskov, K., Gleich, G. J. Structural characterization of contaminants in commercial preparations of melatonin by online HPLC-electrospray ionization-tandem mass spectrometry. Adv. Exp. Med. Biol., 467, 769-777 (1999).
30. Barth, H., Berg, P. A., Klein, R. Is there any relationship between eosinophilia-myalgia syndrome (EMS) and fibromyalgia syndrome (FMS)? An analysis of clinical and immunological data. Adv. Exp. Med. Biol., 467, 487-496 (1999).
31. Barth. H., Klein, R., Berg, P. A. L-Tryptophan contaminant 'peak E' induces the release of IL-5 and IL-10 by peripheral blood mononuclear cells from patients with functional somatic syndrome. Clin. Exp. Immunol., 126, 187-192 (2001).
32. Huether, G., Kochen, W., Simat, T. J., Steinhart, H., eds. Tryptophan, serotonin and melatonin: Basic aspects and applications (Advances in Experimental Medicine and Biology), Springer, 1999. (ISBN-10: 0306462044, ISBN-13: 978-0306462047)
33. Philen, R. M., Posada de la Paz, M., Terracini, B., Kilbourne, E. "Epidemiology of toxic oil syndrome: advances since 1992." Toxic oil syndrome ten years of progress, Terracini, B., ed. Copenhagen, World Health Organization Regional Office for Europe. 2004. (ISBN 92-890-1063-0)
34. Grandjean, P., Tarkowski, S., eds. Toxic Oil Syndrome: Mass food poisoning in Spain. Copenhagen, World Health Organization Regional Office for Europe, 1984, 92p. (ISBN 9289010215)
35. Abaitua Borda, I., Posada de la Paz, M. "Clinical findings." Toxic oil syndrome: Current knowledge and future perspectives. Copenhagen, World Health Organization Regional Office for Europe, 1992, p. 25-35. (ISBN 9289013052)
36. Vazquez Roncero, A., Maestro Duran, R., Ruiz Gutierrez, V. New aniline derivatives in toxic oil syndrome: Toxicity in mice of 3 -phenylamino-1,2 -propanediol and its fatty acid mono- and diesters. Grasas Aceites, 35, 330-331 (1984).
37. Sanchez-Porro, P., Posada de la Paz, M., de Andrez Copa, P., Giménez Ribota, O., Abaitua Borda, I. Toxic oil syndrome: Survival in the whole cohort between 1981 and 1995. J. Clin. Epidemiol., 56. 701-708 (2003).
38. Estirado de Cabo, E., Posada de la Paz, M., de Andrés Copa, P., Plaza Cano Mdel, M., García de Aguinaga, M. L., Suarez Alvarez, C., Braun Saro, B. Carpal tunnel syndrome. A new feature in the natural history of TOS? Eur. J. Epidemiol, 18, 983-993 (2003).
39. del Pozo, V., de Andres, B., Gallardo, S., Cardaba, B., de Arruda-Chaves, E., Cortegano, M. I., Jurado, A., Palomino, P., Oliva, H., Aguilera, B., Posada, M., Lahoz, C. Cytokine mRNA expression in lung tissue from toxic oil syndrome patients: A TH2 immunological mechanism. Toxicology, 118, 61-70 (1997). (Pubitemid 27110845) 41 Ruiz-Mendez, M. V., Posada de la Paz, M., Abián, J., Calaf, R. E., Blount, I., Castro-Molero, N., Philen, R., Gelpi, E. Storage time and deodorization temperature influence the formation of aniline-derived compounds in denatured rapeseed oils. Food Chem. Toxicol., 39, 91-96 2001
40. 42PosadadelaPaz.M.,Philen.R.M.,Schurz,H.,Hill,R.H.,Ribota,O.G.,Cámara,A.G.,Kilbourne,E.M.,Abaitua,I.Epidemiologicevidenceforanewclassofcompoundsassociatedwithtoxicoilsyndrome.Epidemiology,10,130-134(1999).(Pubitemid29093948)
41. Ladona, M. G., Bujons, J., Messeguer, A., Ampurdances, C., Morato, A., Corbella, J. Biotranformation and clearance of 3-(phenylamino) propane-1,2-diol, a compound present in samples related to toxic oil syndrome, in C 57BL/6 and A/J mice. Chem. Res. Toxicol., 12, 1127-1137 (1999).
42. Bujons, J., Ladona, M. G. Messeguer, A., Morato, A., Ampurdanes, C. Metabolism of (R)- and (S)-3-(phenylamino) propane-1,2-diol in C 57 BL/6-and A/J-strain mice. Identification of new metabolites with potential toxicological significance to the toxic oil syndrome. Chem. Res. Toxicol., 14, 1097-1106 (2001).
43. Martinez-Cabot, A., Morato, A., Messeguer, A. Synthesis and stability studies of the glutathione and Nacetylcysteine adducts of an iminoquinone reactive intermediate generated in the biotransformation of 3-(Nphenylamino)propane-1,2-diol: Implications for toxic oil syndrome. Chem. Res. Toxicol., 18, 1721-1728 (2005).
44. Martinez-Cabot, A., Morató, A., Commandeur, J. N., Vermeulen, N. P., Messeguer, A. In vitro bioactivation of 3-(N-phenylamino)propane-1,2-diol by human and rat liver microsomes and recombinant P450 enzymes. Implications for toxic oil syndrome. Chem. Res. Toxicol., 20, 1218-1224 (2007).
45. Serrano-Mollar, A., Fernandez-Zabalegui, L., Bulbena, O., Gelpi, E., Closa, D. Induction of c-fos messenger RNA by 3-(N-phenylamino)-l,2-propanediol esters, compounds related to toxic oil syndrome. Chem.-Biol. Inter., 149, 117-123 (2004).
46. Kaphalia, B. S., Khan, M. F., Ansari, G. A. S. Fatty acid anilides: In vivo formation and relevance to toxic oil syndrome. J. Biochem. Mol. Toxicol., 13, 269-277 (1999).
47. Bell, S. A., Page, S., Baumgartner, B., Berking, C., Haas, M., Eisele, T., Neumeier, D., Brand, K. Involvement of nuclear factor-kappa B in a murine model for the acute form of autoimmune-like toxic oil syndrome. Toxicol. Appl. Pharmacol., 157, 213-221 (1999).
48. Cai, P., Khan, M. F., Kaphalia, B. S., Ansari, G. A. Immunotoxic response of oleic acid anilide and its hydrolysis products in female MRL (+/+) mice. J. Immunotoxicol., 2, 231-236 (2005). (Pubitemid 41789907)
49. Cardaba, B., Ezendam, J., Gallardo, S., del Pozo, V., Izuierdo, M., Martin, C., Cortegano, I., Aceituno, E., Rojo, M., Arrieta, I., Palomino, P., Posada, M., Lahoz, C. DR2 antigens are associated with severity of disease in toxic oil syndrome (TOS). Tissue Antigens, 55, 110-117 (2000).
50. Ladona, M. G., Izquierdo-Martínez, M., Posada de la Paz, M. P., de la Torre, R., Ampurdanés, C., Segura, J. Sanz, E.J. Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish toxic oil syndrome. Environ. Health Perspect., 109, 369-375 (2001).
51. Cardaba, B., del Pozo, V., Gallardo, S., Palomino, P., Posada, M., Lahoz, C. Genetic approaches in the understanding of toxic oil syndrome. Toxicol. Lett., 161, 83-88 (2006).
52. Berking, C., Hobbs, M. V., Châtelain, R., Meurer, M., Bell, S. A. Strain-dependent cytokine profile and susceptibility to oleic acid anilide in a murine model of the toxic oil syndrome. Toxicol. Appl. Pharmacol., 148, 222-228 (1998).
53. Bell, S. A., Kuntze, I., Caputo, A., Chatelain, R. Straindependent in vitro and in vivo effects of oleic acid anilides on splenocytes and T cells in a murine model of the toxic oil syndrome. Food Chem. Toxicol., 40, 19-24 (2002).
54. Koller, L. D., Stang, B. V., Hall, J. A., Posada de la Paz, M., Ruiz Mendez, M. V. Immunoglobulin and autoantibody responses in MRL/lpr mice treated with 'toxic oil'. Toxicology, 178, 119-133 (2002).
55. Weatherill, A. R., Stang, B. V., O'Hara. K., Koller, L. D., Hall, J. A. Investigating the onset of autoimmunity in A. SW mice following treatment with 'toxic oil'. Toxicol. Lett., 136, 205-216 (2003).
56. Mayeno, A. N., Benson, L. M., Naylor, S., Colberg-Beers, M., Puchalski, J. T., Gleich, G. J. Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: A chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome. Chem. Res. Toxicol., 8, 911-916 (1995).
57. Martinez-Cabot, A., Messeguer, A. Generation of quinoneimine intermediates in the bioactivation of 3-(Nphenylamino)alanine (PAA) by human liver microsomes: A potential link between eosinophilia-myalgia syndrome and toxic oil syndrome. Chem. Res. Toxicol., 20, 1556-1562 (2007).
58. WHO. Toxic Oil Syndrome, Current Knowledge and Future Perspectives. European Series No. 42. Copenhagen, World Health Organization Regional Office for Europe, 1992, 163 p. (ISBN 9289013052)
59. WHO. Toxic Oil Syndrome, Ten Years of Progress. Copenhagen, World Health Organization Regional Office for Europe, 2004. (ISBN 92-890-1063-0) http://www.euro.who.int/document/e84423.pdf)
60. Gelpi. E., de la Paz, M. P., Terracini, B., Abaitua, I., de la Camara, A. G., Kilbourne, E. M., Lahoz, C., Nemery, B., Philen, R. M., Soldevilla, L. Tarkowski, S. The Spanish toxic oil syndrome 20 years after its onset: A multidisciplinary review of scientific knowledge. Environ. Health Perspect., 110, 457-464 (2002).